SUZHOU, China, March 5, 2025 -- CD (Suzhou) Biopharma, an innovative biotechnology company focused on developing next-generation immunotherapies, today announced three upcoming poster presentations related to its lead program CD-001 at the American Association for Cancer Research (AACR) Annual Meeting 2025, to be held in Chicago, Illinois.
Presentation Details
Abstract #3426: Preclinical development of CD-001, a novel fusion protein combining PD-1 blockade with IL-21 for solid tumors
Date and Location: Monday, April 28, 2025, Poster Section 35, Poster Board Number 21, 2:00 p.m. - 5:00 p.m.
Abstract #CT144: Phase I investigator-initiated clinical trial of CD19CAR-T cells secreting PD-1-targeted IL-21 in relapsed/refractory B-cell non-Hodgkin lymphoma
Date and Location: Tuesday, April 29, 2025, Poster Section 48, Poster Board Number 10, 9:00 a.m. - 12:00 p.m.
Abstract #CT145: Phase I investigator-initiated clinical trial of BCMACAR-T cells secreting PD-1-targeted IL-21 in relapsed/refractory multiple myeloma
Date and Location: Tuesday, April 29, 2025, Poster Section 48, Poster Board Number 11, 9:00 a.m. - 12:00 p.m.
About CD-001
CD-001, the company's leading clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy, designed to target PD-1 positive CD8⁺ T cells using an anti-PD-1 antibody and engineered IL-21 mutant, aims to address unmet medical needs in oncology and viral infections.
Preclinical studies have demonstrated potent anti-tumor activity across multiple tumor models in mice, with a favorable safety and pharmacokinetic profile observed in non-human primate toxicology studies. The program has received IND clearance from both the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for advanced solid tumors, with first-in-human (FIH) solid tumor trials currently underway. An additional IND application for hematological malignancies is currently under review by NMPA.
About CD (Suzhou) Biopharma
Founded in 2021, CD Biopharma is a rapidly advancing clinical-stage biotech company focused on developing innovative therapies across a broad spectrum of immunotherapy areas, including oncology, viral infections, and autoimmune diseases. The company's proprietary Bispecific Fusion Protein (BsFP) platform and IMmune-Enhanced (IME) cell technology, which enable advanced cell modification, continue to drive breakthrough research and clinical outcomes that transform patient care. CD Biopharma is headquartered in Suzhou, China, with additional research operations in Beijing, China.
